Axiron Net Sales, quarter to March 2015
Released
Released
Announcement PDF
ACRUX (ACR) - ASX ANNOUNCEMENT
24th APRIL 2015
AXIRON NET SALES, QUARTER TO 31 MARCH 2015
Acrux (ASX: ACR) today confirmed that Eli Lilly reported Axiron net sales of USD$39.1
million in its financial results for the quarter ended 31 March 2015. Net sales reported by
Lilly for the same quarter to 31 March 2014 were USD$39.5 million.
Royalties payable for the quarter are expected to be favourable versus the previous
corresponding quarter based on exchange rate movements in the AUD:USD.
Contact
Michael Kotsanis, Chief Executive Officer: 03 8379 0100
About Acrux
Acrux is an Australian drug delivery company, developing and commercialising a range of
patient-preferred, patented pharmaceutical products for global markets, using its innovative
technology to administer drugs through the skin.
The Acrux technology, used in marketed products including Axiron®, Evamist® and
Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing
penetration enhancers, that when applied topically, deposits drug through the skin for long
acting delivery.
Acrux has three products marketed by licensees in the USA, three products approved in
Europe, and further products at earlier stages of development.
Share your feedback
Discover